Ischemic Stroke
Conditions
Interventions
Observation group:None
Sponsors
The First affiliated hospital, Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Patient's age >= 18 years old; 2. Clinically diagnosed with ischemic stroke (in accordance with the diagnostic criteria in the "2023 Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke"), with an onset time = 3 months from the last stroke episode; 3. Pre-stroke modified Rankin Scale (mRS) score < 3 points; 4. National Institutes of Health Stroke Scale (NIHSS) score of 4-25 points at the time of this stroke onset; 5. The patient is capable of self-care or has a long-term caregiver who can assist in completing medication records and cooperating with follow-ups; 6. The subject or their guardian voluntarily signs the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Complicated with intracranial hemorrhagic diseases: hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, etc.; 2. Patients planned for or having already undergone intracranial/extracranial vascular surgeries (such as CEA, CAS, extracranial-intracranial bypass), brain tumor resection, or other surgeries that may affect the prognosis; 3. Suffering from diseases with hemorrhagic tendency: platelet count 16 seconds, international normalized ratio (INR) > 1.5, activated partial thromboplastin time (APTT) > 45 seconds, or diagnosed with hemophilia, von Willebrand disease, severe liver disease (Child-Pugh Class C), etc.; 4. Complicated with severe cardiac, pulmonary, or renal insufficiency (creatinine > 2.0 mg/dl or 177 µmol/L), severe liver impairment (AST/ALT > 1.5 × ULN), malignant tumors, etc., with a life expectancy of less than 6 months; 5. Patients during pregnancy, lactation, with potential pregnancy, or planning for pregnancy; 6. Patients with contraindications or intolerance to antiplatelet drugs (such as aspirin, clopidogrel) or anticoagulant drugs in the past, and unable to switch to other standardized secondary preventive drugs; 7. Patients with severe mental disorders, meeting the diagnostic criteria for "schizophrenia spectrum disorders, acute episodes of bipolar disorder" in the International Classification of Diseases (ICD-11); dementia patients with a Mini-Mental State Examination (MMSE) score < 18 points and clinically diagnosed with Alzheimer's disease or vascular dementia; 8. Having participated in other clinical drug studies within 3 months prior to the date of obtaining informed consent, or currently participating in other clinical drug studies; 9. Patients deemed unsuitable for this clinical study by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Modified Rankin Scale score; | — |
Secondary
| Measure | Time frame |
|---|---|
| National Institutes of Health Stroke Scale score;Stroke recurrence;Mini-Mental State Examination score;Montreal Cognitive Assessment score;Morisky Medication Adherence;Incidence rate of other vascular events;Modified Rankin Scale Score; | — |
Countries
China
Contacts
Public ContactYuhua Fan
The First affiliated hospital, Sun Yat-sen University
Outcome results
None listed